Table 3 Estimated comparative effectiveness of a third dose of BNT162b2 and mRNA-1273 vaccines in subgroups defined by baseline characteristics during a period spanning Delta- and Omicron-variant predominance (20 October 2021 to 15 February 2022)

From: Comparative effectiveness of third doses of mRNA-based COVID-19 vaccines in US veterans

 

No. of eventsa

16-week no. of events/10,000 persons (95% CI)

Risk difference no of events/10,000 persons (95% CI)

Risk ratio (95% CI)

BNT162b2

mRNA-1273

BNT162b2

mRNA-1273

BNT162b2 vs mRNA-1273

Age <70 yr

Documented infection

888

723

409.1 (364.9, 441.5)

340.4 (294.4, 361.9)

68.8 (26.4, 122.1)

1.20 (1.07, 1.39)

Symptomatic COVID-19

56

40

21.0 (15.3, 26.8)

17.5 (9.6, 24.2)

3.5 (−5.0, 13.3)

1.20 (0.77, 2.21)

Hospitalization

67

24

30.5 (17.5, 33.1)

13.4 (6.8, 18.2)

17.1 (3.7, 22.7)

2.28 (1.23, 3.88)

ICU admission

19

6

9.5 (3.6, 13.3)

4.4 (0.4, 7.6)

5.1 (−1.1, 10.8)

2.16 (0.81, 15.00)

Death

–

–

–

–

–

–

Age ≥70 yr

Documented infection

716

617

301.8 (275.6, 332.9)

277.3 (245.1, 298.8)

24.5 (−9.0, 75.9)

1.09 (0.97, 1.31)

Symptomatic COVID-19

57

36

20.8 (16.2, 29.3)

13.9 (8.8, 18.3)

6.9 (1.1, 17.1)

1.50 (1.07, 2.76)

Hospitalization

63

34

26.5 (20.0, 34.9)

15.4 (9.7, 22.6)

11.1 (1.5, 21.0)

1.72 (1.08, 2.98)

ICU admission

17

13

7.4 (4.0, 11.4)

6.7 (2.3, 12.6)

0.8 (−6.2, 6.4)

1.11 (0.42, 3.31)

Death

12

8

5.0 (1.5, 7.4)

4.1 (1.0, 7.2)

0.9 (−4.0, 5.0)

1.21 (0.35, 5.37)

Race, White

Documented infection

1,197

919

355.2 (315.0, 364.6)

287.8 (266.8, 314.1)

67.4 (13.4, 85.7)

1.23 (1.04, 1.31)

Symptomatic COVID-19

100

44

26.7 (17.9, 29.2)

11.3 (9.2, 18.3)

15.4 (2.5, 17.4)

2.37 (1.16, 2.59)

Hospitalization

99

45

28.0 (21.3, 33.7)

14.5 (9.4, 21.4)

13.4 (3.4, 20.8)

1.92 (1.17, 3.07)

ICU admission

26

15

7.4 (4.0, 10.2)

5.8 (2.3, 10.9)

1.7 (−5.3, 6.0)

1.29 (0.52, 3.14)

Death

14

9

4.4 (1.5, 6.2)

3.3 (0.6, 5.7)

1.1 (−2.8, 4.0)

1.35 (0.45, 6.34)

Race, Black

Documented infection

390

352

359.1 (317.4, 411.1)

318.4 (274.8, 353.0)

40.7 (−10.7, 115.0)

1.13 (0.97, 1.39)

Symptomatic COVID-19

26

22

19.7 (11.7, 28.1)

19.1 (10.1, 26.9)

0.6 (−10.4, 14.4)

1.03 (0.59, 2.37)

Hospitalization

29

18

29.9 (16.0, 43.4)

18.4 (7.4, 27.0)

11.5 (−3.7, 29.1)

1.63 (0.85, 4.41)

ICU admission

–

–

–

–

–

–

Death

–

–

–

–

–

–

Months since completion of COVID-19 vaccine primary series, 6–7

Documented infection

508

389

330.5 (290.7, 358.3)

254.8 (227.6, 286.8)

75.7 (20.8, 108.3)

1.30 (1.08, 1.45)

Symptomatic COVID-19

35

19

20.2 (10.7, 23.4)

12.2 (6.8, 19.6)

8.0 (−4.6, 12.6)

1.66 (0.71, 2.75)

Hospitalization

34

12

23.2 (15.3, 31.3)

9.3 (5.2, 20.1)

13.9 (−0.2, 21.5)

2.49 (0.99, 4.33)

ICU admission

–

–

–

–

–

–

Death

–

–

–

–

–

–

Months since completion of COVID-19 vaccine primary series, 8

Documented infection

587

519

341.3 (306.1, 371.8)

320.5 (269.7, 347.0)

20.8 (−16.2, 86.3)

1.06 (0.95, 1.31)

Symptomatic COVID-19

46

25

23.1 (17.0, 33.8)

12.9 (8.4, 19.4)

10.2 (1.3, 21.4)

1.79 (1.07, 3.16)

Hospitalization

43

22

25.2 (17.1, 34.2)

13.4 (6.1, 18.0)

11.8 (3.2, 24.8)

1.88 (1.21, 4.54)

ICU admission

8

6

4.7 (2.1, 11.0)

3.9 (0.6, 7.0)

0.7 (−2.7, 8.0)

1.19 (0.48, 10.32)

Death

–

–

–

–

–

–

Months since completion of COVID-19 vaccine primary series, ≥9

Documented infection

395

315

305.9 (259.6, 334.6)

317.1 (233.8, 359.7)

−11.1 (−72.1, 78.0)

0.96 (0.79, 1.33)

Symptomatic COVID-19

32

20

23.9 (13.7, 31.7)

18.0 (9.0, 26.8)

5.9 (−7.4, 18.2)

1.33 (0.68, 2.55)

Hospitalization

43

21

34.9 (19.1, 43.6)

37.2 (11.9, 83.7)

−2.3 (−60.2, 24.1)

0.94 (0.30, 2.82)

ICU admission

15

6

11.3 (4.6, 16.2)

24.6 (1.2, 65.5)

−13.3 (−59.4, 12.4)

0.46 (0.09, 10.92)

Death

–

–

–

–

–

–

  1. Recipients of a third dose of the BNT162b2 vaccine were matched in a 1:1 ratio to recipients of a third dose of the mRNA-1273 vaccine according to the following variables: calendar date of third dose, calendar month of second mRNA vaccine dose, age, sex, race (except for subgroup analyses restricted to race), urbanicity of residence, geographic location coded as categories of Veterans Integrated Services Network and number of SARS-CoV-2 tests performed in the past year. Estimates were calculated only in analyses in which there were more than 5 outcome events in each vaccine group under comparison.
  2. aThe sum of events across subgroups may not equal the sum of events in the overall population because the entire analysis (including matching) was repeated after stratification of the population according to baseline characteristics.
Back to article page